Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29024527 | 1.00 | HDAC2 (0.39) | HDAC2HDAC1ACACBGPR183KDM4E | |
| SCHEMBL26631332 | 0.88 | HDAC2 (0.40) | HDAC2HDAC1ACACBGPR183KDM4E | |
| SCHEMBL26631442 | 0.86 | CHRM4 (0.41) | HDAC2HDAC1ACACBGPR183GPR119 | |
| SCHEMBL25411120 | 0.83 | CHRM4 (0.33) | — | |
| SCHEMBL29427005 | 0.81 | HDAC2 (0.38) | HDAC2HDAC1ACACBGPR183KDM4E | |
| SCHEMBL29427006 | 0.77 | DPP4 (0.38) | HDAC2HDAC1ACACBKDM4EMAPT | |
| SCHEMBL29497473 | 0.77 | DPP4 (0.38) | HDAC2HDAC1ACACBKDM4EMAPT | |
| SCHEMBL30503521 | 0.77 | DPP4 (0.38) | HDAC2HDAC1ACACBKDM4EMAPT | |
| SCHEMBL29024670 | 0.77 | DPP4 (0.38) | HDAC2HDAC1ACACBKDM4EMAPT | |
| SCHEMBL23228669 | 0.76 | CHRM4 (0.56) | HDAC2HDAC1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063784-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | HDAC2 659/4885HDAC1 271/4885ACACB 61/4885 |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | HDAC2 620/4885HDAC1 254/4885ACACB 60/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HDAC2 620/4885HDAC1 254/4885ACACB 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.